Back to discover
Drug

Valine

In clinical development
Emerging researchEarly-to-mid developmentSteady momentum
Also known as (2S)-2-Amino-3-methylbutanoic acid, (S)-Valine, 2-Amino-3-methylbutyric acid, Aminosyn 10%, Sulfite-Free+42 more

(2S)-2-Amino-3-methylbutanoic acid, (S)-Valine, 2-Amino-3-methylbutyric acid, Aminosyn 10%, Sulfite-Free, Aminosyn 3.5 % M, Sulfite Free, Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn 8.5%, Sulfite-Free, Aminosyn II 10 %, Aminosyn II 15%, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 %, Sulfite-Free, Aminosyn-HBC 7 %, Sulfite-Free, Aminosyn-PF 10 %, Sulfite-Free, Aminosyn-PF 7%, Branchamin, Clinisol 15, Freamine III 10, Hepatamine 8, Hepatasol, L-(+)-alpha-Aminoisovaleric acid, L-Valine, L-alpha-Amino-beta-methylbutyric acid, L-valin, Nephramine, Plenamine, PremaSol, ProSol, ProcalAmine 3, Travasol 10, Travasol 10%, Trophamine, Trophamine 10 %, Trophamine 6 %, Val, Clinimix 4.25/10, Clinimix 4.25/25, Clinimix 4.25/5, Clinimix 5/15, Clinimix 5/20, Clinimix 5/25, Clinimix E 2.75/5, Clinimix E 4.25/10, Clinimix E 4.25/5, Clinimix E 5/15, Clinimix E 5/20, Clinimix E 5/25.

4
Research papers
2
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Valine
Aliases & brands
(2S)-2-Amino-3-methylbutanoic acid(S)-Valine2-Amino-3-methylbutyric acidAminosyn 10%, Sulfite-FreeAminosyn 3.5 % M, Sulfite FreeAminosyn 8.5 % with Electrolytes, Sulfite-FreeAminosyn 8.5%, Sulfite-FreeAminosyn II 10 %Aminosyn II 15%Aminosyn II 8.5 % with Electrolytes, Sulfite-FreeAminosyn II 8.5 %, Sulfite-FreeAminosyn-HBC 7 %, Sulfite-FreeAminosyn-PF 10 %, Sulfite-FreeAminosyn-PF 7%BranchaminClinisol 15Freamine III 10Hepatamine 8HepatasolL-(+)-alpha-Aminoisovaleric acidL-ValineL-alpha-Amino-beta-methylbutyric acidL-valinNephraminePlenaminePremaSolProSolProcalAmine 3Travasol 10Travasol 10%TrophamineTrophamine 10 %Trophamine 6 %ValClinimix 4.25/10Clinimix 4.25/25Clinimix 4.25/5Clinimix 5/15Clinimix 5/20Clinimix 5/25Clinimix E 2.75/5Clinimix E 4.25/10Clinimix E 4.25/5Clinimix E 5/15Clinimix E 5/20Clinimix E 5/25
RxNorm CUI
11115
ChEMBL ID
CHEMBL43068
UNII
HG18B9YRS7

Clinical trials

3 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
3
registered trials across all phases
LATEST COMPLETION 2018
2
Active studies
2
Recruiting
1
Completed
PHASE DISTRIBUTIONn = 3
Early Phase 12Phase 11

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
19892020
Major research themes5
Angiotensin II Type 1 Receptor Blockers1Angiotensin Receptor Antagonists1Bifidobacterium animalis1Gastrointestinal Microbiome1Neuronal Plasticity1
Journals, researchers & institutions
Top journals
  • The New England journal of medicine2
  • Genome biology1
  • The Journal of neuroscience : the official journal of the Society for Neuroscience1
Leading researchers
  • Califf RM2
  • Leimberger JD2
  • McMurray JJ2
  • Pfeffer MA2
  • Rouleau JL2
  • Solomon SD2
  • Velazquez EJ2
  • Zelenkofske S2
Leading institutions
free-text, unnormalised
  • Brigham and Women's Hospital2
  • College of Veterinary Medicine1
  • Hubei Key Laboratory of Agricultural Bioinformatics1
  • Key Laboratory of Development of Veterinary Diagnostic Products1
  • National Key Laboratory of Agricultural Microbiology1
  • Novogene Bioinformatics Institute1

Related diseases

2 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 6 of the same disease areas as Valine in the shared literature.

6 shared diseases2 shared papers

Studied across 6 of the same disease areas as Valine in the shared literature.

6 shared diseases2 shared papers

Studied across the same disease area as Valine in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials